ConductScience.org, home

Paper41007627

Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.

Jin Y and 4 others. Biomedicines, 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab. Papers, record 41007627. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007627

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.4, provisional
iCite
Revised in PubMed
2025-09-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jin YYanyanhttps://orcid.org/0000-0001-5822-8962
2Xie YYihttps://orcid.org/0000-0002-6234-5325
3Fu HHaidong
4Liu FFei
5Mao JJianhuahttps://orcid.org/0000-0002-6076-3806

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References109

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126923204Plasma cells as an innovative target in autoimmune disease with renal manifestations.Nat Rev Nephrol2016https://conductscience.org/library/papers/26923204PubMed
235779372Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.Mult Scler Relat Disord2022https://conductscience.org/library/papers/35779372PubMed
339966139Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies.Pediatr Nephrol2025https://conductscience.org/library/papers/39966139PubMed
438552841A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.Kidney Int2024https://conductscience.org/library/papers/38552841PubMed
521187443Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.J Immunol2011https://conductscience.org/library/papers/21187443PubMed
636071552Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.Nephrol Dial Transplant2023https://conductscience.org/library/papers/36071552PubMed
737777061Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.Am J Kidney Dis2024https://conductscience.org/library/papers/37777061PubMed
839874224CD19-CAR T-cell therapy induces deep tissue depletion of B cells.Ann Rheum Dis2025https://conductscience.org/library/papers/39874224PubMed
936223961Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.BMJ Open2022https://conductscience.org/library/papers/36223961PubMed
1040052241The Role of IL-10-Producing Regulatory B Cells in Children With Primary Nephrotic Syndrome.Nephrology (Carlton)2025https://conductscience.org/library/papers/40052241PubMed
1139431468Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.J Am Soc Nephrol2025https://conductscience.org/library/papers/39431468PubMed
1235716094A critical role of the podocyte cytoskeleton in the pathogenesis of glomerular proteinuria and autoimmune podocytopathies.Acta Physiol (Oxf)2022https://conductscience.org/library/papers/35716094PubMed
1334788412Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Rheumatology (Oxford)2022https://conductscience.org/library/papers/34788412PubMed
1435110735Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.Nature2022https://conductscience.org/library/papers/35110735PubMed
1535354600Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.J Am Soc Nephrol2022https://conductscience.org/library/papers/35354600PubMed
1640017729Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.Drugs Context2025https://conductscience.org/library/papers/40017729PubMed
1734094516Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.Clin Kidney J2021https://conductscience.org/library/papers/34094516PubMed
1833091355Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.Lancet Haematol2020https://conductscience.org/library/papers/33091355PubMed
1936137752Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients.J Am Soc Nephrol2023https://conductscience.org/library/papers/36137752PubMed
2037842819Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.Expert Rev Neurother2023https://conductscience.org/library/papers/37842819PubMed

See all 109 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42630345A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy.Am J Transl Res2026https://conductscience.org/library/papers/42630345PubMed
42518347Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers.Front Pharmacol2026https://conductscience.org/library/papers/42518347PubMed
42495251Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Front Pediatr2026https://conductscience.org/library/papers/42495251PubMed
42491171Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy.Am J Transl Res2026https://conductscience.org/library/papers/42491171PubMed
42414649Obinutuzumab as a primary anti-CD20 agent in pediatric frequently relapsing and steroid-dependent nephrotic syndrome.Pediatr Nephrol2026https://conductscience.org/library/papers/42414649PubMed
41659867B cells in acquired aplastic anemia and the exploratory role of rituximab: considerations in pediatric and female patients.Front Immunol2026https://conductscience.org/library/papers/41659867PubMed
41488676Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up.Front Immunol2025https://conductscience.org/library/papers/41488676PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007627

GET https://conductscience.org/api/papers/v1/41007627/references?page=2